Twist Bioscience Launches $250 Million Public Stock Offering to Support R&D, Manufacturing Expansion, and Long-Term Growth
Twist Bioscience Corporation (Nasdaq: TWST), a biotechnology company recognized for its synthetic DNA technology platform and expanding portfolio of genomics and life sciences products, has announced the commencement of an underwritten public offering of common stock valued at $250 million. The financing initiative is intended to strengthen the company’s balance sheet while providing additional capital to support research and development, manufacturing expansion, product innovation, and other strategic corporate priorities.
In addition to the primary offering, Twist plans to grant the underwriting syndicate a 30-day option to purchase up to an additional $37.5 million of common stock. If exercised in full, the total value of the offering could reach $287.5 million, providing the company with even greater financial flexibility to pursue its long-term growth strategy.
The announcement underscores Twist Bioscience’s commitment to investing in innovation and expanding its commercial capabilities as demand for synthetic biology, genomics, precision medicine, and molecular diagnostics continues to grow worldwide.
Strengthening Financial Resources for Future Expansion
The proposed public offering represents an important component of Twist Bioscience’s capital allocation strategy. By raising additional equity financing, the company seeks to ensure it has sufficient financial resources to continue advancing both existing programs and future growth opportunities.
According to the company, proceeds from the offering, together with its current cash reserves, cash equivalents, and marketable securities, will primarily support investments across several key business areas.
Among the highest priorities are continued research and development initiatives designed to expand the company’s technology platform and accelerate the introduction of new products. Twist also plans to use a portion of the proceeds to increase manufacturing capacity, enabling it to meet growing customer demand while improving production efficiency and scalability.
Remaining funds are expected to support general corporate purposes, including working capital requirements and operational flexibility.
The financing strategy reflects management’s confidence in the company’s long-term business outlook and its intention to continue investing aggressively in innovation despite broader market uncertainties.
Supporting Innovation Through Research and Development
Research and development remains central to Twist Bioscience’s business model.
Since its founding, the company has built its reputation around its proprietary silicon-based DNA synthesis platform, which enables rapid, high-throughput production of synthetic DNA at scale.
This technology has applications across numerous scientific disciplines, including drug discovery, antibody development, industrial biotechnology, agriculture, diagnostics, and academic research.
As customer demand for synthetic biology solutions continues to expand, ongoing investment in research will remain essential for maintaining technological leadership and developing next-generation products.
The additional capital raised through the proposed offering will help finance new research programs aimed at improving DNA synthesis technologies, expanding product capabilities, and supporting emerging applications in genomics and precision medicine.
Investment in innovation is particularly important within the biotechnology sector, where rapid technological advancements continually reshape competitive dynamics.
Expanding Manufacturing Capacity
Alongside research investments, Twist Bioscience intends to dedicate a significant portion of the proceeds toward expanding its manufacturing capabilities.
As demand for synthetic DNA products continues to increase globally, manufacturing scalability has become a critical competitive advantage.
Expanding production capacity enables the company to serve a growing customer base while maintaining product quality, reducing turnaround times, and supporting large-scale commercial partnerships.
Manufacturing investments may include facility expansion, equipment upgrades, automation technologies, and operational improvements designed to increase efficiency while maintaining the company’s high standards for precision and quality.
By strengthening its manufacturing infrastructure, Twist aims to position itself for continued growth across both existing and emerging markets.
Broadening Product Offerings
The proposed financing will also support continued expansion of Twist Bioscience’s product portfolio.
Over recent years, the company has diversified beyond synthetic DNA production into multiple adjacent markets, including next-generation sequencing, antibody discovery, synthetic genes, DNA data storage research, and precision medicine applications.
Broadening product offerings allows the company to serve a wider range of customers across pharmaceutical companies, biotechnology firms, academic institutions, healthcare organizations, and industrial biotechnology developers.
New product development also provides opportunities to enter additional high-growth markets while strengthening long-term revenue diversification.
As scientific research increasingly relies on advanced genomic technologies, expanding product capabilities remains a strategic priority for sustaining future commercial growth.
Maintaining Financial Flexibility
In addition to targeted investments, a portion of the proceeds will be allocated toward general corporate purposes and working capital.
Maintaining strong liquidity is especially important for biotechnology companies, which often operate in rapidly evolving markets requiring ongoing investment and operational flexibility.
Working capital supports routine business operations, including inventory management, customer support, employee recruitment, infrastructure development, and strategic initiatives.
A strengthened balance sheet also enhances the company’s ability to respond to new business opportunities, pursue potential partnerships, or make strategic investments as market conditions evolve.
The financing therefore provides not only growth capital but also additional financial resilience.
Details of the Public Offering
Twist Bioscience intends to offer $250 million worth of newly issued common stock through an underwritten public offering.
All shares offered in the transaction are being sold directly by the company.
In addition, the underwriters have been granted an option, exercisable for 30 days following the offering, to purchase up to $37.5 million of additional shares.
Such overallotment options, often referred to as “greenshoe” options, are common in public equity offerings. They provide underwriting banks with flexibility to stabilize trading activity and meet investor demand following the offering.
If exercised in full, the additional purchase option would increase the total proceeds available to Twist Bioscience.
However, the company noted that the offering remains subject to customary market conditions and other closing requirements.
As with any proposed public financing, there can be no assurance regarding whether the transaction will ultimately be completed or the final pricing, timing, or size of the offering.
Experienced Investment Banks Lead the Transaction
Twist Bioscience has assembled a group of well-established investment banks to manage the proposed financing.
Serving as joint book-running managers are:
- Goldman Sachs & Co. LLC
- William Blair
- Leerink Partners
- Guggenheim Securities
Book-running managers coordinate investor marketing, determine pricing in consultation with the issuer, manage institutional allocations, and oversee execution of the offering.
The participation of multiple experienced investment banks reflects the significance of the transaction and provides access to a broad institutional investor base.
These firms also assist in regulatory compliance and facilitate communication between the company and prospective investors throughout the offering process.
Regulatory Framework
The proposed offering is being conducted pursuant to an automatic shelf registration statement filed on Form S-3 with the U.S. Securities and Exchange Commission (SEC).
The registration statement was filed on June 18, 2026, and became effective immediately upon filing under applicable SEC regulations.
An automatic shelf registration allows eligible public companies to register securities in advance, providing flexibility to access capital markets efficiently when financing opportunities arise.
Under this framework, companies may issue various types of securities without filing an entirely new registration statement for each offering, reducing administrative requirements and enabling quicker execution.
Investors considering participation in the offering are encouraged to review the preliminary prospectus supplement together with the accompanying prospectus for detailed information regarding the transaction.
These documents provide important disclosures concerning the company’s financial condition, business operations, risk factors, and terms of the proposed offering.
No Offer Where Prohibited
As is customary for public securities transactions, Twist Bioscience emphasized that its announcement does not constitute an offer to sell securities or a solicitation to purchase securities in jurisdictions where such transactions would be unlawful.
Sales of securities may occur only after compliance with applicable securities laws and regulatory requirements in each relevant jurisdiction.
The company also noted that completion of the offering remains dependent upon prevailing market conditions and satisfaction of customary closing requirements.
Supporting Long-Term Strategic Growth
The announcement highlights Twist Bioscience’s continued focus on building a scalable business capable of supporting long-term expansion across multiple areas of life sciences and biotechnology.
Demand for synthetic biology technologies has grown substantially over the past decade as pharmaceutical companies, academic researchers, and industrial biotechnology organizations increasingly rely on synthetic DNA for drug discovery, diagnostics, gene editing, vaccine development, and precision medicine.
By investing simultaneously in research, manufacturing infrastructure, and commercial expansion, Twist seeks to strengthen its competitive position while creating additional opportunities for future innovation.
The proposed financing also provides resources that may help the company respond to emerging scientific trends, technological advances, and customer requirements across rapidly evolving biotechnology markets.
Twist Bioscience’s proposed $250 million public offering represents a strategic investment in the company’s future growth and innovation agenda. If completed, the financing will provide significant additional capital to accelerate research and development, expand manufacturing capacity, broaden product offerings, and maintain the operational flexibility needed to compete in the fast-moving biotechnology industry.
Supported by its proprietary synthetic DNA platform and growing presence across genomics, molecular biology, and precision medicine, Twist Bioscience continues to position itself as a key technology provider for researchers and life sciences organizations worldwide. While the final terms of the offering remain subject to market conditions, the planned capital raise reflects management’s confidence in the company’s long-term strategy and its commitment to advancing technologies that support scientific discovery, therapeutic development, and the future of synthetic biology.
About Twist Bioscience Corporation
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.
We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.
Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all.